Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 273 Carcinoma, Non-Small-Cell Lung 244 Carcinoma, Renal Cell 144 Neoplasms 99 Neoplasm Metastasis 99 Squamous Cell Carcinoma of Head and Neck 88 Carcinoma, Hepatocellular 87 Colorectal Neoplasms 82 Lung Neoplasms 77 Stomach Neoplasms 59 Pancreatic Neoplasms 56 Carcinoma, Transitional Cell 50 Hodgkin Disease 47 Urinary Bladder Neoplasms 42 Head and Neck Neoplasms 42 Breast Neoplasms 40 Ovarian Neoplasms 37 Triple Negative Breast Neoplasms 34 Small Cell Lung Carcinoma 33 Brain Neoplasms 33 Sarcoma 32 Prostatic Neoplasms 32 Glioblastoma 32 Kidney Neoplasms 29 Recurrence 28 Multiple Myeloma 25 Esophageal Neoplasms 24 Uveal Melanoma 23 Skin Neoplasms 23 Uterine Cervical Neoplasms 22

Interventions

belzutifan 5 gallium Ga 68 dotatate 3 Everolimus 2 Blood Specimen Collection 2 vatalanib 1 tanespimycin 1 spartalizumab 1 palbociclib 1 lenvatinib 1 cabozantinib 1 Vorinostat 1 Sunitinib 1 Ranibizumab 1 Propranolol 1 PT2385 1 Oxygen-15 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Fluorodeoxyglucose F18 1 Exome Sequencing 1 Bevacizumab 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

von Hippel-Lindau Disease × Nivolumab × Clear all

NCT07405164 2026-05-29

MK-6482-043

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡